<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475772</url>
  </required_header>
  <id_info>
    <org_study_id>PIPAC-OV2</org_study_id>
    <secondary_id>2014-001034-28</secondary_id>
    <nct_id>NCT02475772</nct_id>
  </id_info>
  <brief_title>A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis</brief_title>
  <official_title>A Phase I, Single-arm, Open-label, Three Step Dose Escalation Study With Intraperitoneal Pressurized Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clemens Tempfer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fifteen women with recurrent ovarian cancer will be treated by an intraperitoneal
      chemotherapy with cisplatin and doxorubicin in three escalating dosage schedules. The aim of
      the study is to evaluate the safety and tolerability of doxorubicin and cisplatin every 4
      weeks for three courses using a three-group, dose-escalation protocol with fixed
      dose-density. The time Frame for the assessment of the Primary outcome is therefore 12 weeks.
      Predefined toxicity criteria will be applied using CTCAE version 4.0 criteria. The study
      hypothesis is that local and systemic toxicity will increase with increasing dosage of
      cisplatin and doxorubicin during three repeated PIPAC courses with no CTCAE grade 4 and 5
      events in any treatment group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective phase I, single-arm (nonrandomized), open-label, three step
      dose-escalation study with cisplatin and doxorubicin applied as PIPAC in 15 patients with
      recurrent ovarian cancer and peritoneal cancer.

      The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and
      cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will
      receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in
      50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3
      mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for
      three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will
      not be changed.

      The aim of this study is to evaluate the safety and tolerability of doxorubicin and cisplatin
      every 4-6 weeks for three courses using a three-group, dose-escalation protocol with fixed
      dose-density. The time Frame for the assessment of the Primary outcome is therefore 12 weeks.
      Predefined toxicity criteria will be applied using CTCAE version 4.0 criteria, documented
      after the first, second, and third course of treatment. Clinical examinations will include
      abdominal computed tomography (CT) scans after the first, second, and third course of
      treatment, cardiac echocardiography before the first, second, and third course of treatment,
      and a clinical neurological assessment before the first, second, and third course of
      treatment. Pharmacological studies will include hematologic, liver, and renal function tests
      as well as cisplatin and doxorubicin plasma levels with blood samples drawn before, during,
      and up to 12 h after the start of each PIPAC course.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events according to CTCAE criteria</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit according to RECIST criteria</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma concentrations of cisplatin and doxorubicin</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin and doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin and doxorubicin will be applied under pressure into the abdomen via laparoscopic trocars. The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin and doxorubicin</intervention_name>
    <description>The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.</description>
    <arm_group_label>Cisplatin and doxorubicin</arm_group_label>
    <other_name>Cisplatin TEVA, Doxorubicin 50 HEXALÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cisplatin and doxorubicin</intervention_name>
    <description>intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme</description>
    <arm_group_label>Cisplatin and doxorubicin</arm_group_label>
    <other_name>Intraperitoneal chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. clinical and/or radiological evidence of PC,

          2. age between 18 and 85 years with a diagnosis of recurrent ovarian cancer with disease
             progression after at least one line of previous intravenous chemotherapy with a
             platinum compound,

          3. blood and electrolyte counts, liver, and renal function parameters within 10% of the
             normal range established in the respective laboratory of the study institution,

          4. provision of written informed consent, and

          5. postmenopausal status.

        Exclusion Criteria:

          1. extraabdominal metastatic disease, with the exception of isolated pleural
             carcinomatosis/effusion,

          2. chemotherapy or surgery within the last four weeks prior to the first PIPAC
             application,

          3. previous treatment with maximum cumulative doses of doxorubicin, daunorubicin,
             epirubicin, idarubicin, and/or other anthracyclines and anthracenediones,

          4. a history of allergic reaction to cisplatin or other platinum containing compounds or
             doxorubicin,

          5. severe renal impairment, myelosuppression, severe hepatic impairment, severe
             myocardial insufficiency, recent myocardial infarction or severe cardiac arrhythmia,

          6. immunocompromised status such as immunosuppressive therapy or a known disease of the
             immune system,

          7. previous enrolment in the present study, and

          8. previous intraabdominal chemotherapy or intraabdominal antibody therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemen^s B Tempfer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruhr University Bochum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruhr University Bochum, Germany, Marienhospital Herne</name>
      <address>
        <city>Herne</city>
        <state>North-Rhine Westphalia</state>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Tempfer CB, Celik I, Solass W, Buerkle B, Pabst UG, Zieren J, Strumberg D, Reymond MA. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol. 2014 Feb;132(2):307-11. doi: 10.1016/j.ygyno.2013.11.022. Epub 2013 Nov 23.</citation>
    <PMID>24275155</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Clemens Tempfer</investigator_full_name>
    <investigator_title>Chairman, Clinic Director</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>recurrent</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>intraperitoneal</keyword>
  <keyword>cisplatin</keyword>
  <keyword>doxorubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

